DOV vs EMR Stock Comparison
Dover Corporation vs Emerson Electric Co.
DOV leads
DOV leads by 1 AIQ points, primarily on Risk Resilience and Value, having only recently taken the lead back from EMR.
Fragile: 3 of 6 evidence groups support DOV, the lead recently changed hands, and its current signal state is conflicted.
Dover Corporation
Emerson Electric Co.
The Algovestiq AIQ Score currently favors DOV over EMR, 51 versus 50 as of Sep 5, 2026. DOV's advantage is driven primarily by stronger risk resilience and value, while EMR holds the stronger momentum profile. DOV also shows the weaker technical structure relative to its 50-day moving average. 3 of 6 covered evidence groups favor DOV today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 1 points. DOV lead: Reversed — EMR led by 3 AIQ points 30 sessions ago; DOV now leads by 1.
Compare Dover Corporation and Emerson Electric Co. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Compare DOV and EMR against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum25%22 vs 39EMR +17
- Risk Resilience15%72 vs 55DOV +17
- Value30%59 vs 49DOV +10
- Quality30%56 vs 56Even
3 of 6 evidence groups favor DOV. DOV’s edge is concentrated in risk resilience and value; EMR keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-09-04, compared against the prior scored session 2026-09-03.
No factor moved materially.
No new signals fired.
No factor moved materially.
No new signals fired.
DOV's lead was unchanged in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — DOV and EMR both carry a full feed there.
The central trade-off
DOV (Dover Corporation): the stronger current systematic profile, led by risk resilience and value.
EMR (Emerson Electric Co.): the counter-case, on momentum, technicals — but at materially higher volatility, 26.1% against 16.7%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
DOVDOV on the overall AIQ Score, which weights Quality and Value at 30% each.
Growth
DOVDOV on combined revenue and EPS growth.
Value
DOVDOV on the peer-relative Value factor, by 10 points.
Momentum
EMREMR on the Momentum factor, by 17 points.
Lower downside
DOVDOV on Risk Resilience, by 17 points.
Analyst upside
DOVDOV on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | DOV | EMR | Note |
|---|---|---|---|
| Implied upside to target | +28.5% | +7% | DOV has more room |
| Target dispersion | +21% | +31.2% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 9 | 9 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor DOV. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 51 vs 50 |
| Fundamentals | Even | revenue growth 6.6% vs 6.8%; EPS growth 31.1% vs 16.4%; TTM ROE 15% vs 12.7%; gross margin 39.6% vs 53.2%; operating margin 16.9% vs 20.1% |
| Valuation | DOV | Value 59 vs 49 |
| Technicals | EMR | Price vs 50-day -7.3% vs 2.4%; vs 200-day -9% vs 5.4% |
| Risk Resilience | DOV | Risk Resilience 72 vs 55 |
| Analyst expectations | DOV | Target upside 28.5% vs 7% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of DOV and EMR and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 1 points. (argues the conclusion is provisional)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Signal direction runs against the verdict: the leader is net-bearish while the laggard is net-bullish. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on DOV.
How the comparison changed
120 daily snapshots · Apr 23 – Sep 4DOV lead: Reversed — EMR led by 3 AIQ points 30 sessions ago; DOV now leads by 1.
- Today
- DOV +1
- 51 vs 50
- 7 sessions ago
- EMR +1
- 51 vs 52
- 30 sessions ago
- EMR +3
- 56 vs 59
- 90 sessions ago
- DOV +6
- 57 vs 51
The lead changed hands 5 times in this window, most recently on Aug 31 when DOV moved ahead of EMR.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 4 bearish, conflicted
- Death Cross Active — bearish, trend, long horizon (0.90%)
- Keltner Channel Breakdown — bearish, volatility, short horizon
- RSI Oversold - Potential Bounce — bullish, momentum, short horizon
3 bullish / 1 bearish, conflicted
- Golden Cross Active — bullish, trend, long horizon (4.70%)
- RSI Oversold - Potential Bounce — bullish, momentum, short horizon
- Uptrend Structure Active — bullish, trend, long horizon
DOV leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.95%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.74%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1EMR closes the Risk Resilience gap — currently 17 points behind, the largest single contributor to DOV's edge.
- 2EMR generates a confirmed bullish trend signal it does not currently carry, such as MACD Bullish Crossover or EMA Ribbon Expansion Bullish.
- 3DOV's conflicting signal state resolves bearish — it currently carries 1 bullish and 4 bearish rules at once.
- 4A regime shift changes factor weighting — the composite weights Quality and Value at 30% each, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
Split| Metric | DOV | EMR |
|---|---|---|
| Revenue growth (YoY) | 6.6% | 6.8% |
| EPS growth (YoY) | 31.1% | 16.4% |
| Gross margin | 39.6% | 53.2% |
| Operating margin | 16.9% | 20.1% |
| Return on equity (TTM) | 15% | 12.7% |
| Debt to equity | 0.42 | 0.68 |
Performance
EMR leads 6 of 6 windows| Metric | DOV | EMR |
|---|---|---|
| 1 week (5 sessions) | -5.3% | -4.8% |
| 1 month (20 sessions) | -9.4% | -4.3% |
| 3 months (63 sessions) | -10.5% | 5.7% |
| 6 months (126 sessions) | -11.4% | 5.6% |
| Year to date | -2.1% | 13.2% |
| 1 year (252 sessions) | 8.7% | 14.3% |
Technicals
EMR has the stronger structure| Metric | DOV | EMR |
|---|---|---|
| RSI (14) | 25.8 | 28.7 |
| ADX (14) | 23.1 | 24.6 |
| Price vs 50-day | -7.3% | 2.4% |
| Price vs 200-day | -9% | 5.4% |
| Volatility (1M, annualized) | 16.7% | 26.1% |
Risk
DOV is the more resilient| Metric | DOV | EMR |
|---|---|---|
| Beta | 0.94 | 1.58 |
| Sharpe ratio | 0.32 | 0.5 |
| Sortino ratio | 0.52 | 0.76 |
| Max drawdown | -19% | -23.7% |
| Current drawdown | -18.1% | -8.6% |
| Annualized volatility | 26.3% | 32.3% |
| Value at risk (95%) | -2.5% | -3.5% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, DOV or EMR?
On the Algovestiq AIQ Score, DOV is the stronger of the two as of Sep 5, 2026, scoring 51 against EMR's 50. The edge comes from risk resilience and value. EMR is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is DOV or EMR the better buy right now?
DOV carries the stronger systematic profile as of Sep 5, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 1 points. Treat the lead as provisional.
Why does the AIQ Score favor DOV over EMR?
The composite weights Quality at 30%, Value at 30%, Momentum at 25% and Risk Resilience at 15%. EMR leads Momentum by 17 points; DOV leads Risk Resilience by 17 points; DOV leads Value by 10 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, DOV or EMR?
Analyst price targets imply +28.5% upside for DOV and +7% for EMR, so the Street currently favors DOV. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, DOV or EMR?
DOV is the better-valued of the two on the peer-relative Value factor. DOV on the peer-relative Value factor, by 10 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, DOV or EMR?
DOV on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, DOV or EMR?
EMR on the Momentum factor, by 17 points. Momentum carries 25% of the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, DOV or EMR?
DOV is the more resilient of the two, so the other name carries the higher downside risk. DOV on Risk Resilience, by 17 points. The Risk Resilience factor weights 15% of the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is DOV more profitable than EMR?
The profitability evidence is mixed: gross margin 39.6% vs 53.2%; operating margin 16.9% vs 20.1%; ttm roe 15% vs 12.7%. DOV leads on one measure and EMR on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is DOV's lead over EMR getting stronger or weaker?
DOV lead: Reversed — EMR led by 3 AIQ points 30 sessions ago; DOV now leads by 1. This is measured from 120 daily comparison snapshots between 2026-04-23 and 2026-09-04. The lead has changed hands 5 times in that window, most recently on 2026-08-31, when DOV moved ahead of EMR.
What would change the DOV vs EMR verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: EMR closes the Risk Resilience gap — currently 17 points behind, the largest single contributor to DOV's edge; EMR generates a confirmed bullish trend signal it does not currently carry, such as MACD Bullish Crossover or EMA Ribbon Expansion Bullish; DOV's conflicting signal state resolves bearish — it currently carries 1 bullish and 4 bearish rules at once; a regime shift changes factor weighting — the composite weights Quality and Value at 30% each, so a rotation toward either would move the result most.
What do the current signals say about DOV and EMR?
DOV: 1 bullish / 4 bearish, conflicted. EMR: 3 bullish / 1 bearish, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on DOV is Death Cross Active (bearish, long horizon). On EMR it is Golden Cross Active (bullish, long horizon).
Compare DOV and EMR with others
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality (30%), Value (30%), Momentum (25%) and Risk (15%). Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.